Matheus Simonato1,2; Ali N. Azadani3, PhD; John Webb1, MD; Jonathon Leipsic1, MD; Ran Kornowski4, MD; Alec Vahanian5, MD; David Wood6, MD; Nicolo Piazza7, MD; Susheel Kodali8, MD; Jian Ye1, MD; Brian Whisenant9, MD; Diego Gaia2, MD; Mina Aziz1, MD; Tilak Pasala9, MD; Julinda Mehilli10, MD; Harindra C. Wijeysundera11, MD; Didier Tchetche12, MD; Neil Moat13, MD; Rui Teles14, MD; Anna Sonia Petronio15
1. St. Paul’s Hospital, Vancouver, BC, Canada; 2. Escola Paulista de Medicina – UNIFESP, São Paulo, Brazil; 3. University of Denver, Denver, CO, USA; 4. Rabin Medical Center, Petah Tikva, Israel; 5. Hôpital Bichat-Claude Bernard, Paris, France; 6. Vancouv
Aims: Transcatheter heart valve (THV) implantation in failed bioprosthetic valves (valve-in-valve [ViV]) offers an alternative therapy for high-risk patients. Elevated post-procedural gra